随着新型冠状病毒肺炎（COVID-19）在国内快速爆发，国家卫生健康委员会办公厅和国家中医药管理局办公室推出不同的诊疗方案。目前根据COVID-19危重症患者的临床特征及中医辨证认为气阴两虚证为主要证型之一，生脉散为备选中成药。注射用益气复脉（冻干）是生脉散的现代制剂，对COVID-19的可能病理过程及注射用益气复脉用于心血管疾病的COVID-19治疗的药效作用及临床应用可行性进行了探讨，以期为COVID-19的中医治疗提供参考。

As the rapid outbreak of epidemic novel coronavirus pneumonia (COVID-19) in China, National Health Commission of People's Republic of china and National Administration of Traditional Chinese Medicine have launched different programs of diagnosis and treatment. Currently, combining the clinical characteristics of critically patients, the syndrome differentiation of traditional Chinese medicine maintain that Qi-Yin deficiency is one of the main syndrome types, and Shengmai Powder is the main alternative Chinese traditional medicine. Yiqi Fumai lyophilized Injection (YQFM) is a modern preparation derived from Shengmai Powder. In the present study, we explored the potential pathological process of COVID-19. Meanwhile, the pharmacological effects as well as the possibility of clinical application of YQFM for the treatment of COVID-19 patients with cardiovascular diseases were also evaluated. This review will provide evidences for clinicians and patients in the treatment of COVID-19 using Chinese traditional treatment.

R259;R285.6

天津市科技计划项目“注射用益气复脉（冻干）标准提升成果转化”（18YFCZZC00430）